Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bedford Laboratories, a division of Ben Venue Laboratories, has announced the acquisition of Cafcit injection and Cafcit oral solution from Mead Johnson & Company. Cafcit is indicated for the short-term treatment of apnea in premature infants between 28 and less than 33 weeks gestational age.
Subscribe to our email newsletter
Bedford Laboratories is now the reference listed drug holder. Bedford Laboratories will supply latex-free Cafcit (caffeine citrate) injection as 60mg/3 mL single-use vials individually boxed and Cafcit oral solution as 60mg/3 mL single-use vials, 10 vials per child-resistant container.
David Gaugh, vice president and general manager of Bedford, said: “The acquisition of Cafcit demonstrates our continued commitment to build the most comprehensive and cost-effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price.”